2008 Annual Meeting | Neural Repair
| 09:00 AM - 09:20 AM |
Welcome and Introduction
Michael Weinrich, MD |
|
| 09:00 AM - 05:00 PM | Abstract |
001 - Theta Burst Stimulation (TBS) in Motor Rehabilitation after Stroke: Preliminary Results on a Two-Week Treatment Protocol for the Upper Limb
|
| 09:00 AM - 05:00 PM | Abstract |
001 - Subthalamic Nucleus Stimulation Affects Orbitofrontal Cortex in Facial Emotion Recognition: A PET Study
|
| 09:00 AM - 05:00 PM | Abstract |
002 - Electrical Stimulation of Spared Corticospinal Axons Strengthens Connections with and Induces Outgrowth to Spinal Motor Circuits after Injury
|
| 09:00 AM - 05:00 PM | Abstract |
002 - Response of Gait Dyscoordination to FES Gait Training after Stroke
|
| 09:00 AM - 05:00 PM | Abstract |
003 - A Quantitative Method To Assess Numbers of Axons Regenerating through a Tissue-Engineered Scaffold into Distal Spinal Cord after Transection Injury in Rats
|
| 09:00 AM - 05:00 PM | Abstract |
003 - Development of an RNAi Strategy for AD
|
| 09:00 AM - 05:00 PM | Abstract |
004 - Monitoring Post-Stroke Plasticity in Patients with Good Functional Recovery: A Comparison between Diffusion Tensor and Qball Magnetic Resonance Imaging
|
| 09:00 AM - 05:00 PM | Abstract |
004 - Stability of the Blind Spot as a Measure of Fixation Stability in Visual Restoration Therapy
|
| 09:00 AM - 05:00 PM | Abstract |
005 - Effect of Diflunisal on Neurologic Disease in Familial Transthyretin Amyloidosis
|
| 09:00 AM - 05:00 PM | Abstract |
006 - Murine Embryonic (mES) Derived Neural Stem Cells Transplantation Ameliorates Disease Phenotype of a Spinal Muscular Atrophy Model
|
| 09:00 AM - 05:00 PM | Abstract |
007 - Aberrant Channel Subunit Trafficking in the Neurodegenerative KCNC3/R420H SCA13 Phenotype
|
| 09:00 AM - 05:00 PM | Abstract |
008 - Peroxiredoxin 6 [ndash] A Novel Antioxidant Neuroprotective Agent
|
| 09:00 AM - 05:00 PM | Abstract |
009 - Human and Rat Neural Precursor Cells Cross Brain Endothelial Cells: The Implication of CD44
|
| 09:20 AM - 09:45 PM |
Cellular Therapies in Motor Neuron and White Matter Spinal Cord
Douglas A. Kerr, MD, PhD |
|
| 09:55 AM - 10:30 PM |
Rewiring the Injured CNS: Lessons from the Optic Nerve
Larry Benowitz |
|
| 10:30 AM - 11:00 AM |
Abstract presentations
|
|
| 11:00 AM - 11:20 AM |
Break and Posters
|
|
| 11:20 AM - 11:55 PM |
Noninvasive Brain Stimulation in Neurology: Perspectives on the
Alvaro Pascual-Leone, MD, PhD, FÂ鶹´«Ã½Ó³» |
|
| 11:55 AM - 12:30 PM |
Synaptic Plasticity
Gary Lynch, MD |
|
| 12:30 PM - 01:30 PM |
Luncheon
|
|
| 01:30 PM - 02:05 PM |
Treatment of Spinal Cord Injury
Mark H. Tuszynski, MD, PhD, FÂ鶹´«Ã½Ó³» |
|
| 02:05 PM - 02:40 PM |
Restorative Therapies for Stroke
Steven C. Cramer, MD, FÂ鶹´«Ã½Ó³» |
|
| 02:40 PM - 03:10 PM |
Abstract presentation
|
|
| 03:10 PM - 03:30 PM |
Break and Posters
|
|
| 03:30 PM - 04:05 PM |
Brain Neuroprosthesis Interface
Hunter Peckham, PhD |
|
| 04:05 PM - 04:40 PM |
Aphasia Treatment and the Human Mirror System
Steven L. Small, MD, PhD, FÂ鶹´«Ã½Ó³» |
|
| 04:40 PM - 05:00 PM |
Panel discussion
|
| Alvaro Pascual-Leone, MD, PhD, FÂ鶹´«Ã½Ó³» | Dr. Pascual-Leone has received personal compensation for serving as an employee of Linus Health. Dr. Pascual-Leone has received personal compensation for serving as an employee of TI Solutions. Dr. Pascual-Leone has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for BitBrain. Dr. Pascual-Leone has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for AscenZion. Dr. Pascual-Leone has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Neuroelectrics. Dr. Pascual-Leone has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for TetraNeuron. Dr. Pascual-Leone has received personal compensation in the range of $100,000-$499,999 for serving as an officer or member of the Board of Directors for Linus Health. Dr. Pascual-Leone has received personal compensation in the range of $500-$4,999 for serving as an officer or member of the Board of Directors for TI Solutions. Dr. Pascual-Leone has or had stock in TI Solutions. The institution of Dr. Pascual-Leone has received research support from NIH. The institution of Dr. Pascual-Leone has received research support from NSF. The institution of Dr. Pascual-Leone has received research support from Brightfocus Foundation . Dr. Pascual-Leone has received intellectual property interests from a discovery or technology relating to health care. Dr. Pascual-Leone has received publishing royalties from a publication relating to health care. |
| Douglas A. Kerr, MD, PhD | Dr. Kerr has received personal compensation for serving as an employee of Dyne Therapeutics. Dr. Kerr has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for BlueRock Therapeutics. Dr. Kerr has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Trace Neuroscience. Dr. Kerr has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Spolia Therapeutics. Dr. Kerr has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for BlueRock Therapeutics. Dr. Kerr has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for AAVantgarde Therrapeutics. Dr. Kerr has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for Trace Neuroscience. Dr. Kerr has or had stock in Dyne Therapeutics. |
| Steven L. Small, MD, PhD, FÂ鶹´«Ã½Ó³» | No disclosure on file |
| Michael Weinrich, MD | No disclosure on file |
| Mark H. Tuszynski, MD, PhD, FÂ鶹´«Ã½Ó³» | No disclosure on file |
| Steven C. Cramer, MD, FÂ鶹´«Ã½Ó³» | Dr. Cramer has received personal compensation for serving as an employee of University of California. An immediate family member of Dr. Cramer has received personal compensation for serving as an employee of University of California. Dr. Cramer has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Astellas, Alevian, Bayer, BlueRock Therapeutics, BrainQ, Constant Therapeutics, Medtronic, MicroTransponder, Myomo, Myrobalan, NeuroTrauma Sciences, Simcere, and TRCare. Dr. Cramer has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for MUSC. Dr. Cramer has stock in Constant Therapeutics, Panaxium, and TRCare. The institution of Dr. Cramer has received research support from NIH; PCORI; Veterans Administration. |
| Larry Benowitz | No disclosure on file |
| Gary Lynch, MD | No disclosure on file |
| Hunter Peckham, PhD | No disclosure on file |
| Neill R. Graff-Radford, MD, FÂ鶹´«Ã½Ó³» | The institution of Dr. Graff-Radford has received research support from Biogen. The institution of Dr. Graff-Radford has received research support from Lilly. The institution of Dr. Graff-Radford has received research support from Eisai. The institution of Dr. Graff-Radford has received research support from Biogen. Dr. Graff-Radford has received publishing royalties from a publication relating to health care. |
| Raymond P. Roos, MD, FÂ鶹´«Ã½Ó³» | Dr. Roos has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for MedLink. Dr. Roos has stock in Amazon. Dr. Roos has stock in Amgen. Dr. Roos has stock in Apple. Dr. Roos has stock in Cigna. Dr. Roos has stock in IBM. Dr. Roos has stock in Ionis. Dr. Roos has stock in Pfizer. Dr. Roos has received research support from Lohengrin Foundation. |
| Janice F. Wiesman, MD, FÂ鶹´«Ã½Ó³» | No disclosure on file |
| Edgardo Rodriguez-Lebron | No disclosure on file |
| P. James B. Dyck, MD, FÂ鶹´«Ã½Ó³» | Dr. Dyck has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Akcea/Ionis. |
| Aneesh B. Singhal, MD, FÂ鶹´«Ã½Ó³» | An immediate family member of Dr. Singhal has received personal compensation for serving as an employee of Biogen. Dr. Singhal has received personal compensation in the range of $5,000-$9,999 for serving as an Expert Witness for Medicolegal Firms. Dr. Singhal has received research support from NIH-NINDS. Dr. Singhal has received publishing royalties from a publication relating to health care. Dr. Singhal has received publishing royalties from a publication relating to health care. Dr. Singhal has received personal compensation in the range of $500-$4,999 for serving as a Honorarium (Â鶹´«Ã½Ó³») with Biogen. |
| Walter J. Koroshetz, MD, FÂ鶹´«Ã½Ó³» | Dr. Koroshetz has nothing to disclose. |
| Robert L. Ruff, MD, PhD, FÂ鶹´«Ã½Ó³» | No disclosure on file |
| Henry L. Paulson, MD, PhD, FÂ鶹´«Ã½Ó³» | Dr. Paulson has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Exicure. The institution of Dr. Paulson has received research support from National Institutes of Health. Dr. Paulson has a non-compensated relationship as a Member, Nominating committee with American Neurological Association that is relevant to Â鶹´«Ã½Ó³» interests or activities. |
| No disclosure on file | |
| Nereo Bresolin, DR | No disclosure on file |
| Stefan M. Pulst, MD, FÂ鶹´«Ã½Ó³» | Dr. Pulst has received personal compensation in the range of $500-$4,999 for serving as a Consultant for venrock. Dr. Pulst has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Arrowhead. Dr. Pulst has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Leverna. Dr. Pulst has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Â鶹´«Ã½Ó³». Dr. Pulst has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for Leninthal LLC. The institution of Dr. Pulst has received research support from NINDS. Dr. Pulst has received intellectual property interests from a discovery or technology relating to health care. |
| Ole Suhr | The institution of Ole Suhr has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alnylam . The institution of Ole Suhr has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Akcea. The institution of Ole Suhr has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Prothena. The institution of Ole Suhr has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Intellia. The institution of Ole Suhr has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Akces. The institution of Ole Suhr has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alnylam. Ole Suhr has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Alnylam. Ole Suhr has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Akcea. The institution of Ole Suhr has received research support from Swedish Heart and Lung Foundation. |
| Randolph S. Marshall, MD, FÂ鶹´«Ã½Ó³» | The institution of Dr. Marshall has received research support from NIH. Dr. Marshall has received publishing royalties from a publication relating to health care. |
| John Martin | No disclosure on file |
| Taro Yamashita, MD, PhD | Dr. Yamashita has nothing to disclose. |
| Nicolas Weiss | No disclosure on file |
| John L. Berk | John L. Berk has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alnylam Pharmaceuticals. John L. Berk has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Ionis Pharmaceuticals. John L. Berk has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Astra Zeneca/IONIS. John L. Berk has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eidos/BridgBio. John L. Berk has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Intellia Therapeutics. John L. Berk has received research support from Alnylam . John L. Berk has received research support from Ionis. John L. Berk has received research support from Eidos/Bridgbio. |
| Daniel H. Geschwind, MD, PhD | Dr. Geschwind has received personal compensation in the range of $100,000-$499,999 for serving as a Consultant for Ovid Therapeutics, Inc.. Dr. Geschwind has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for AcuraStem, Inc.. Dr. Geschwind has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Axial Biotherapeutics, Inc.. Dr. Geschwind has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Falcon Computing. Dr. Geschwind has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Elsevier-Biological Psychiatry. Dr. Geschwind has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for NYAS. Dr. Geschwind has received personal compensation in the range of $50,000-$99,999 for serving as an Expert Witness for Covington& Burling LLP. Dr. Geschwind has stock in none related to talk. The institution of Dr. Geschwind has received research support from CurePSP. The institution of Dr. Geschwind has received research support from NINDS. The institution of Dr. Geschwind has received research support from Rainwater Charitable Foundation. The institution of Dr. Geschwind has received research support from NIMH. The institution of Dr. Geschwind has received research support from NINDS. The institution of Dr. Geschwind has received research support from NIH. The institution of Dr. Geschwind has received research support from The Simons Foundation. The institution of Dr. Geschwind has received research support from NIH/NIMH. The institution of Dr. Geschwind has received research support from Adelson Medical Research Foundation. The institution of Dr. Geschwind has received research support from NINDS. The institution of Dr. Geschwind has received research support from NIMH. The institution of Dr. Geschwind has received research support from NINDS/NIA. The institution of Dr. Geschwind has received research support from NIH/NIMH. The institution of Dr. Geschwind has received research support from Adelson Medical Research Foundation. The institution of Dr. Geschwind has received research support from NIH/NINDS. The institution of Dr. Geschwind has received research support from NIH/NIMH. The institution of Dr. Geschwind has received research support from NIH/NIMH. The institution of Dr. Geschwind has received research support from Adelson Medical Research Foundation. The institution of Dr. Geschwind has received research support from U of Virginia and NIH/NIMH. The institution of Dr. Geschwind has received research support from NIH. The institution of Dr. Geschwind has received research support from NIH/NHGRI. The institution of Dr. Geschwind has received research support from NIH/NIMH. Dr. Geschwind has received intellectual property interests from a discovery or technology relating to health care. Dr. Geschwind has received intellectual property interests from a discovery or technology relating to health care. Dr. Geschwind has received intellectual property interests from a discovery or technology relating to health care. Dr. Geschwind has received intellectual property interests from a discovery or technology relating to health care. |
| Giancarlo Comi, MD | Dr. Comi has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Janssen. Dr. Comi has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Bristol Myers Squibb. Dr. Comi has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Comi has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Janssen. Dr. Comi has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Bristol Myers Squibb. Dr. Comi has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novartis. Dr. Comi has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Aspen Healthcare. Dr. Comi has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Sanofi. Dr. Comi has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Sanofi. Dr. Comi has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Rewind. |
| Penelope Talelli | No disclosure on file |
| Beverly Davidson, PhD | No disclosure on file |
| Jason Carmel, MD | No disclosure on file |
| A. Gregory Sorensen, MD | No disclosure on file |
| Stefania Corti, MD, PhD | Dr. Corti has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Corti has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Corti has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sarepta. |
| Giovanni Coppola, MD | Dr. Coppola has received personal compensation for serving as an employee of Regeneron. Dr. Coppola has received stock or an ownership interest from Regeneron. |
| Pierre-Olivier Couraud | No disclosure on file |
| Sanjay P. Singh, MD, FÂ鶹´«Ã½Ó³» | Dr. Singh has nothing to disclose. |
| Janis Daly, MS PhD | No disclosure on file |
| Alice Fredrickson, MD | No disclosure on file |
| Robert Spinner | No disclosure on file |
| Jose G. Romano, MD, FÂ鶹´«Ã½Ó³» | Dr. Romano has stock in Vycor Medical/NovaVision. The institution of Dr. Romano has received research support from NIH/NINDS. The institution of Dr. Romano has received research support from NIH/NHLBI. |
| Duong Huynh, PhD | No disclosure on file |
| Michael F. Waters, MD, PhD, FÂ鶹´«Ã½Ó³» | Dr. Waters has nothing to disclose. |
| Paul Sauleau, MD | No disclosure on file |
| Cristina Granziera, MD, PhD | The institution of Prof. Granziera has received research support from Novartis. The institution of Prof. Granziera has received research support from Hoffmann La Roche. The institution of Prof. Granziera has received research support from Genzyme Sanofi. The institution of Prof. Granziera has received research support from Biogen. |
| Andrew Knight | Andrew Knight has nothing to disclose. |
| Florence Le Jeune | No disclosure on file |
| Godard De Ruiter, MD | No disclosure on file |
| Marc Verin | Mr. Verin has nothing to disclose. |
| Anthony J. Windebank, MD, FÂ鶹´«Ã½Ó³» | Dr. Windebank has nothing to disclose. |
| Vijay Sharma | No disclosure on file |
| Hock Luen Teoh | No disclosure on file |
| Bernard P. Chan, MD | The institution of Dr. Chan has received research support from National University Hospital, Singapore. |
| Benjamin Yong Qiang Tan | Benjamin Yong Qiang Tan has nothing to disclose. |
| Dushyant R. Damania, MBBS | No disclosure on file |
| Alfonso Alejandra | No disclosure on file |
| Justin Chandler, MD | No disclosure on file |
| Nancy T. Kung | No disclosure on file |
| Anthony Noto, MD | Dr. Noto has nothing to disclose. |